Status:
COMPLETED
Lifestyle Intervention for Patients With Impaired Glucose Regulation
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Overweight and Obesity
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Impaired glucose regulation (IGR) is closely related to overweight/obesity. By studying different dietary patterns (energy-limited diet vs. low-carbohydrate diet) and intensive lifestyle interventions...
Eligibility Criteria
Inclusion
- Age 18-65 years old ② Fasting blood glucose is between 5.6-6.9 mmol/L (100-125mg/dL) or oral glucose tolerance test (OGTT) 2h plasma glucose (2h-PG) is 7.8-11.1 mmol/L (140-200 mg/dL)
- 24 kg/m2 ≤ BMI ≤ 35 kg/m2
- Those who are willing to accept assessment and sign informed consent.
Exclusion
- Patients diagnosed with diabetes or undergoing diabetes treatment;
- Receiving drugs or surgery for weight loss at present or in the past 3 months;
- Receiving corticosteroid or thyroid hormone treatment;
- Secondary obesity caused by endocrine, genetic, metabolic and central nervous system diseases;
- Patients with abnormal liver function (alanine aminotransferase or/and aspartate aminotransferase exceeding the upper limit of normal value 3 times); patients with abnormal renal function (serum creatinine exceeding the upper limit of normal value); suffering from kidney disease and other diseases that need to control protein intake;
- Diseases affecting the digestion and absorption of food (such as chronic diarrhea, constipation, severe gastrointestinal inflammation, active gastrointestinal ulcer, gastrointestinal resection, cholecystitis/cholecystectomy, etc.); ⑦ Suffering from cardiovascular and cerebrovascular diseases, grade 3 hypertension, chronic hepatitis, malignant tumors, anemia, mental illness and memory disorders, epilepsy and other diseases; ⑧ Suffering from infectious diseases such as active tuberculosis and AIDS; ⑨ During pregnancy or lactation; ⑩Patients with physical disabilities and clinicians think it is not suitable to participate in the study (for example, have a serious disease not included in the discharge criteria) or are unwilling to participate in this study.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT04469400
Start Date
May 1 2020
End Date
December 31 2022
Last Update
June 24 2024
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Cixi People's Hospital
Cixi, Zhejiang, China, 315300
2
Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310009
3
Jinhua municipal central hospital
Jinhua, Zhejiang, China, 321000
4
Lishui People's Hospital
Lishui, Zhejiang, China, 323020